Translational and clinical trials that will encompass YAP inhibitors and other molecules targeting the Hippo pathway, alone or in combination with current immunotherapy regimens in cancer treatment, are needed to answer the question of whether the YAP/Hippo pathway can help meet the unmet need of further improving the current good results of immunotherapy in oncology. The gene discussed is YAP1; the disease is cancer.